Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

REGISTER for free or LOG IN to view this content

Become a GOLD or PLATINUM member to access PowerPoint files, presentation audio, and video